Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
2011 expert discussions on stent thrombosis prevention; leaves open validation with modern stents and P2Y12 regimens.
S tent thrombosis is an example of device-induced, platelet- mediated arterial thrombosis.Rates of stent thrombosis can vary from Ͻ1% to Ͼ10% depending on the patient population, genetic predisposition, device type, pharmacological choices, and duration of antiplatelet pharmacotherapy.The Platelet Colloquium is an annual academic-industry-governmental thinktank meeting devoted to identifying research challenges in platelet biology and clinical applications.The latest meeting was held in Washington, DC, on January 25 to 26, 2011, and this review summarizes the discussions of biocompatible stent design, platelet function assessment, and prevention of thrombosis via short-and long-term P2Y 12 platelet receptor antagonism.
No takes yet. Share an insight, caveat, or question.
Granada et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: